Bacteria in the intestine influence motor dysfunction and neuroinflammation in a mouse model of Parkinson’s disease.
November 6, 2000|
HOUSTON. Amgen, the largest biotechnology company in the world, is funding research focusing on disorders that destroy parts of the nervous system. These include Alzheimer's disease, Parkinson's disease, multiple sclerosis and stroke. Medicines for disorders resulting from dysfunction of the neuroendocrine system such as obesity and Type 2 diabetes are also under development. In both areas, Amgen licenses product candidates and technologies that complement its internal drug discovery and develop